NCT05795816CompletedPhase 3
Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms
The Effectiveness of Testofen on Energy, Fatigue, Mental Acuity, and Other Quality of Life Symptoms Post COVID-19 Infection
Source: ClinicalTrials.gov · Last updated 10 Mar 2025
Brief summary (registry, in English)
This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Testofen (a specialised extract of Trigonella foenum-graecum (Fenugreek) seed) compared to placebo on post COVID-19 symptoms in otherwise healthy participants 18 years and over.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (actual)
- First submitted
- 27 Mar 2023
- Start date
- 25 Oct 2023
- Primary completion date
- 30 Jan 2025
- Lead sponsor
- RDC Clinical Pty Ltd
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT05795816
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 150
- From 25 Oct 2023 to the primary completion date, 30 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current malignancy (excluding BCC) or chemotherapy and radiotherapy treatment for malignancy within the previous 2 years
- Receiving/prescribed coumandin (Warfarin), heparin, dalteaparin, enoxaparin or other anticoagulation therapy
- Receiving pharmaceutical treatment for anxiety, libido, low energy
- Active smokers, nicotine use, alcohol, or drug (prescription or illegal substances) abuse
- History of infection in the month prior to the study
- (2) Symptoms must be as a direct result of having contracted COVID. If symptoms only appeared within 2 weeks of a vaccination it will be considered a vaccine injury and not classed as a result of COVID.
- (3) An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.
Other illness
- Unstable or serious illness (e.g., serious mood disorders, neurological disorders such as MS, kidney disease, liver disease, heart conditions, diabetes, thyroid gland dysfunction) (3)
- Allergic to any of the ingredients in the active or placebo formula
- Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
Other
- Symptoms resulting from vaccination (2)
- Chronic past and/or current alcohol use (\>14 alcoholic drinks per week)
- Known pregnant or lactating women
- Participants who have participated in any other related clinical study during the past 1 month
Who the study is looking for
- Adults 18 years and over
- Able to provide informed consent
- Diagnosed with COVID-19 infection (RAT or PCR test) \>4 weeks, but \< 12 months and experiencing post COVID symptoms (1)
- Agree not to participate in another clinical trial while enrolled in this trial
- Common post COVID symptoms may include fatigue, cough, chest pain, hair loss, weakness, joint pain, cardiac issues, neurocognitive impairment including memory loss, and decreased quality of life
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| RDC Clinical Pty Ltd Coordinator of this site? Confirm its status | Brisbane | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.